AUROBINDO PHARMA Financial Statement Analysis
|
||
The Revenues of AUROBINDO PHARMA have increased by 5.97% YoY .
The Earnings Per Share (EPS) of AUROBINDO PHARMA has decreased by -27.21 % YoY. |
REVENUES |
OPERATING MARGIN |
PROFIT AFTER TAX |
EPS |
ROCE |
AUROBINDO PHARMA Last 5 Annual Financial Results
[BOM: 524804|NSE : AUROPHARMA]
Consolidated | Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 |
---|---|---|---|---|---|
Revenues | ₹24,855 Cr | ₹23,455 Cr | ₹24,775 Cr | ₹23,099 Cr | ₹19,564 Cr |
Expenses | ₹21,137 Cr | ₹19,071 Cr | ₹19,441 Cr | ₹18,234 Cr | ₹15,612 Cr |
Operating Profit (Excl OI) | ₹3,719 Cr | ₹4,385 Cr | ₹5,333 Cr | ₹4,864 Cr | ₹3,952 Cr |
Other Income | ₹291 Cr | ₹323 Cr | ₹381 Cr | ₹192 Cr | ₹155 Cr |
Interest | ₹140 Cr | ₹49 Cr | ₹74 Cr | ₹305 Cr | ₹263 Cr |
Depreciation | ₹1,245 Cr | ₹1,127 Cr | ₹1,055 Cr | ₹967 Cr | ₹668 Cr |
Profit Before Tax | ₹2,613 Cr | ₹3,373 Cr | ₹7,344 Cr | ₹3,743 Cr | ₹3,089 Cr |
Profit After Tax | ₹1,928 Cr | ₹2,647 Cr | ₹5,334 Cr | ₹2,844 Cr | ₹2,362 Cr |
Consolidated Net Profit | ₹1,928 Cr | ₹2,648 Cr | ₹5,335 Cr | ₹2,845 Cr | ₹2,365 Cr |
Earnings Per Share (Rs) | ₹32.90 | ₹45.20 | ₹91.05 | ₹48.56 | ₹40.36 |
PAT Margin (%) | 3.79 | 5.54 | 10.98 | 6.02 | 5.89 |
ROE(%) | 7.50 | 11.38 | 27.53 | 18.52 | 18.47 |
ROCE(%) | 9.39 | 12.71 | 30.10 | 18.72 | 17.97 |
Total Debt/Equity(x) | 0.18 | 0.10 | 0.23 | 0.33 | 0.50 |
Key Financials |
||
Market Cap | : | ₹ 67,522.0 Cr |
Revenue (TTM) | : | ₹ 27,894.7 Cr |
Net Profit(TTM) | : | ₹ 2,777.9 Cr |
EPS (TTM) | : | ₹ 47.4 |
P/E (TTM) | : | 24.3 |
Industry Peers & Returns | 1W | 1M | 1Y |
AUROBINDO PHARMA | 6.4% | 7.7% | 87.6% |
SUN PHARMACEUTICAL INDUSTRIES | 1.1% | -6.6% | 56.7% |
CIPLA | 0.2% | -4.4% | 54.3% |
DR REDDYS LABORATORIES | 4.3% | 2.6% | 29.9% |
ZYDUS LIFESCIENCES | 2.2% | -4.6% | 86.6% |
DIVIS LABORATORIES | 4.8% | 18.9% | 23.9% |
MANKIND PHARMA | -1.4% | 1.4% | NA |
TORRENT PHARMACEUTICALS | -1.7% | 3% | 65.8% |
LUPIN | 4.1% | 3% | 131.2% |
AUROBINDO PHARMA Revenues
[BOM: 524804|NSE : AUROPHARMA]
Y-o-Y | 5.97 % |
5 Yr CAGR | 6.17 % |
Years | Revenues | % Change | |
---|---|---|---|
Mar2023 | ₹24,855 Cr | 5.97 | |
Mar2022 | ₹23,455 Cr | -5.32 | |
Mar2021 | ₹24,775 Cr | 7.26 | |
Mar2020 | ₹23,099 Cr | 18.07 | |
Mar2019 | ₹19,564 Cr | - |
AUROBINDO PHARMA Operating Profit
[BOM: 524804|NSE : AUROPHARMA]
Y-o-Y | -15.19 % |
5 Yr CAGR | -1.51 % |
Years | Operating Profit | % Change | |
---|---|---|---|
Mar2023 | ₹3,719 Cr | -15.19 | |
Mar2022 | ₹4,385 Cr | -17.79 | |
Mar2021 | ₹5,333 Cr | 9.64 | |
Mar2020 | ₹4,864 Cr | 23.09 | |
Mar2019 | ₹3,952 Cr | - |
Operating Margins | |
---|---|
Y-o-Y | -19.96 % |
5 Yr CAGR | -7.23 % |
Years | Operating Margin% | % Change | |
---|---|---|---|
Mar2023 | 14.96% | -19.96 | |
Mar2022 | 18.69% | -13.19 | |
Mar2021 | 21.53% | 2.23 | |
Mar2020 | 21.06% | 4.26 | |
Mar2019 | 20.2% | - |
AUROBINDO PHARMA Profit After Tax
[BOM: 524804|NSE : AUROPHARMA]
Y-o-Y | -27.21 % |
5 Yr CAGR | -4.98 % |
Years | Profit After Tax | % Change | |
---|---|---|---|
Mar2023 | ₹1,928 Cr | -27.21 | |
Mar2022 | ₹2,648 Cr | -50.36 | |
Mar2021 | ₹5,335 Cr | 87.51 | |
Mar2020 | ₹2,845 Cr | 20.32 | |
Mar2019 | ₹2,365 Cr | - |
PAT Margins | |
---|---|
Y-o-Y | -31.59 % |
5 Yr CAGR | -10.44 % |
Years | PAT Margin(%) | % Change | |
---|---|---|---|
Mar2023 | 3.79 % | -31.59 | |
Mar2022 | 5.54 % | -49.54 | |
Mar2021 | 10.98 % | 82.39 | |
Mar2020 | 6.02 % | 2.21 | |
Mar2019 | 5.89 % | - |
AUROBINDO PHARMA Earnings Per Share (EPS)
[BOM: 524804|NSE : AUROPHARMA]
Y-o-Y | -27.21 % |
5 Yr CAGR | -4.98 % |
Years | EPS | % Change | |
---|---|---|---|
Mar2023 | ₹33 | -27.21 | |
Mar2022 | ₹45 | -50.36 | |
Mar2021 | ₹91 | 87.50 | |
Mar2020 | ₹49 | 20.32 | |
Mar2019 | ₹40 | - |
AUROBINDO PHARMA Return on Capital Employed (ROCE)
[BOM: 524804|NSE : AUROPHARMA]
Y-o-Y | -26.12 % |
5 Yr CAGR | -14.98 % |
Years | ROCE | % Change | |
---|---|---|---|
Mar2023 | 9.39% | -26.12 | |
Mar2022 | 12.71% | -57.77 | |
Mar2021 | 30.1% | 60.79 | |
Mar2020 | 18.72% | 4.17 | |
Mar2019 | 17.97% | - |
AUROBINDO PHARMA Share Price vs Sensex
Current Share Price | : | ₹1,152.5 |
Current MarketCap | : | ₹ 67,522.0 Cr |
Updated EOD on | : | Apr 30,2024 |
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
AUROBINDO PHARMA | 6.4% |
7.7% |
87.6% |
SENSEX | 1% |
2.8% |
23.9% |
AUROBINDO PHARMA related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE MOMENTUM | 4.3% | 8% | 83.3% |
S&P BSE MID CAP | 3.8% | 7.8% | 68.7% |
S&P BSE 150 MIDCAP | 3.3% | 7.5% | 60.9% |
S&P BSE 400 MIDSMALLCAP | 2.9% | 8.6% | 62.4% |
S&P BSE MIDSMALLCAP | 2.7% | 9.3% | 67.6% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY200 MOMENTUM 30 INDEX | 4.4% | 6.8% | 71.9% |
NIFTY HEALTHCARE | 2.9% | 0.7% | 52.1% |
NIFTY MIDCAP 50 | 2.8% | 5.1% | 60.7% |
NIFTY PHARMA | 2.8% | 0.9% | 52.3% |
NIFTY MIDCAP150 | 2.6% | 7% | 61.1% |
You may also like the below Video Courses
FAQ about AUROBINDO PHARMA Financials
How the annual revenues of AUROBINDO PHARMA have changed ?
The Revenues of AUROBINDO PHARMA have increased by 5.97% YoY .
How the Earnings per Share (EPS) of AUROBINDO PHARMA have changed?
The Earnings Per Share (EPS) of AUROBINDO PHARMA has decreased by -27.21 % YoY .
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs